KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $825.9 million.

  • Supernus Pharmaceuticals' Non-Current Assets rose 1752.74% to $825.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 540.88%. This contributed to the annual value of $682.0 million for FY2024, which is 1307.19% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Non-Current Assets stood at $825.9 million for Q3 2025, which was up 1752.74% from $643.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Non-Current Assets' 5-year high stood at $1.1 billion during Q4 2021, with a 5-year trough of $643.5 million in Q2 2025.
  • For the 5-year period, Supernus Pharmaceuticals' Non-Current Assets averaged around $861.3 million, with its median value being $869.6 million (2023).
  • In the last 5 years, Supernus Pharmaceuticals' Non-Current Assets soared by 4560.58% in 2021 and then crashed by 1898.03% in 2023.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Non-Current Assets stood at $1.1 billion in 2021, then decreased by 10.96% to $968.4 million in 2022, then fell by 18.98% to $784.6 million in 2023, then dropped by 13.07% to $682.0 million in 2024, then increased by 21.09% to $825.9 million in 2025.
  • Its last three reported values are $825.9 million in Q3 2025, $643.5 million for Q2 2025, and $659.7 million during Q1 2025.